PURPOSE: The mechanism by which ocular surface @entity5 (OSSN) responds to topical @entity4020 ( @entity4020 ) is not known. We report the cases of 3 immunosuppressed @entity1 whose @entity5 did not respond to topical @entity4020 therapy. The purpose of this series is to shed light on potential mechanisms of @entity4020 in OSSN. METHODS: Retrospective case series of 3 immunosuppressed @entity1 whose biopsy-proven OSSN did not respond to topical @entity4020 treatment. RESULTS: Three white, immunosuppressed males (mean age 70 years, range 66-76) were diagnosed with OSSN. Topical @entity4020 1 million units/mL was administered 4 times a day and used for a mean of 5 months (range 2-7 mo) without an adequate response. All @entity1 were then switched to @entity1487 . Successful eradication of OSSN was achieved in 2 cases, and improvement of OSSN in another. The latter @entity1 was switched to @entity1138 with subsequent resolution of OSSN. CONCLUSIONS: These cases suggest that an intact immune system may be an important link between @entity4020 therapy and @entity5 resolution. As such, topical @entity4020 may not be an optimal choice for @entity1 with underlying immunosuppression. It may be more effective in this @entity1 population to switch to a non-immune-modulating therapy such as @entity1487 or @entity1138 -C.

Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'squamous neoplasia', 'tumors'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin', 'mitomycin-C'] @entity4020 :: ('3440', 'Gene') :: ['IFNa2b', 'interferon-alpha-2b'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity5 :: (MESH:D009369,Disease) :: ['Squamous Neoplasia']
